Recognition and Management of Toxic Erythema of Chemotherapy for the Inpatient Dermatologist

Author(s):  
Nari Lee ◽  
Lida Zheng
2021 ◽  
Author(s):  
Angela Lu ◽  
Alyson Endicott ◽  
Sally Y. Tan ◽  
Daniel M. Klufas ◽  
Eric Merrill ◽  
...  

2020 ◽  
Vol 26 (9) ◽  
Author(s):  
Erin Jennings ◽  
Simo Huang ◽  
Jason B Lee ◽  
Jisun Cha ◽  
Sylvia Hsu

2016 ◽  
Vol 20 (5) ◽  
pp. 481-483 ◽  
Author(s):  
Sophie Vadeboncoeur ◽  
Benoît Côté

Background: Doxorubicin is an antineoplastic agent frequently used in diverse cancer regimens. Cutaneous adverse effects have frequently been reported with its use. However, a flagellate-like dermatitis is not mentioned in the literature. Objective: The investigators report a case of toxic erythema of chemotherapy with a flagellate pattern induced by doxorubicin. Methods and Results: A 75-year-old woman with endometrial cancer received doxorubicin as part of her treatment. After her third cycle, she presented a pruritic vesiculobullous eruption, with linear elements that left hyperpigmented streaks on follow-up. A biopsy was compatible with a drug eruption. Conclusion: Doxorubicin is a well-known cause of toxic erythema of chemotherapy. As seen in this patient, the investigators suggest that it also be added to the list of causes of flagellate dermatosis.


2016 ◽  
Vol 2 (6) ◽  
pp. 476-481 ◽  
Author(s):  
Sabrina M. Smith ◽  
Philip B. Milam ◽  
Stephanie K. Fabbro ◽  
Alejandro A. Gru ◽  
Benjamin H. Kaffenberger

2008 ◽  
Vol 59 (3) ◽  
pp. 524-529 ◽  
Author(s):  
Jean L. Bolognia ◽  
Dennis L. Cooper ◽  
Earl J. Glusac

Sign in / Sign up

Export Citation Format

Share Document